- Home
- ODD vs AGIO Comparison
ODD vs AGIO Comparison
Compare ODD & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- AGIO
- Stock Information
- Founded
- ODD 2018
- AGIO 2007
- Country
- ODD Israel
- AGIO United States
- Employees
- ODD N/A
- AGIO N/A
- Industry
- ODD
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ODD
- AGIO Health Care
- Exchange
- ODD Nasdaq
- AGIO Nasdaq
- Market Cap
- ODD 2.6B
- AGIO 2.6B
- IPO Year
- ODD 2023
- AGIO 2013
- Fundamental
- Price
- ODD $39.75
- AGIO $53.78
- Analyst Decision
- ODD Buy
- AGIO Buy
- Analyst Count
- ODD 6
- AGIO 7
- Target Price
- ODD $53.67
- AGIO $52.33
- AVG Volume (30 Days)
- ODD 375.8K
- AGIO 726.1K
- Earning Date
- ODD 11-06-2024
- AGIO 10-31-2024
- Dividend Yield
- ODD N/A
- AGIO N/A
- EPS Growth
- ODD 80.44
- AGIO N/A
- EPS
- ODD 1.64
- AGIO 11.80
- Revenue
- ODD $620,646,000.00
- AGIO $32,871,000.00
- Revenue This Year
- ODD $27.40
- AGIO $33.38
- Revenue Next Year
- ODD $20.03
- AGIO $163.06
- P/E Ratio
- ODD $24.18
- AGIO $4.56
- Revenue Growth
- ODD 29.59
- AGIO 36.79
- 52 Week Low
- ODD $30.34
- AGIO $20.96
- 52 Week High
- ODD $50.36
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ODD 45.25
- AGIO 59.21
- Support Level
- ODD $40.06
- AGIO $43.25
- Resistance Level
- ODD $47.08
- AGIO $62.58
- Average True Range (ATR)
- ODD 2.39
- AGIO 2.73
- MACD
- ODD -0.03
- AGIO 0.71
- Stochastic Oscillator
- ODD 23.33
- AGIO 54.47
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.